After losing the school science fair, Billy takes revenge on the winner — the act that leads to his "naughty list" designation.
After losing the school science fair, Billy takes revenge on the winner — the act that leads to his "naughty list" designation.
The actor has said she wasn't aware microphones would pick up everything said in the castle walls.
M1 Kliniken AG / Key word(s): Personnel/Miscellaneous M1 Kliniken AG: Mr. Patrick Brenske joins the board of HAEMATO AG. Promotion of the product business as core task of the integration of the Haemato Group into the M1 Kliniken AG - Group 30-Nov-2020 / 15:30 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. M1 Kliniken AG: Mr. Patrick Brenske joins the board of HAEMATO AG. Promotion of the product business as core task of the integration of the Haemato Group into the M1 Kliniken AG - Group Berlin, 30.11.2020 - M1 Kliniken AG announces that as of today Mr. Patrick Brenske will join the Management Board of HAEMATO AG. At the same time, Mr. Brenske will resign from the Management Board of M1 Kliniken AG, with Dr. Walter von Horstig from now on acting as sole member of the Management Board. Mr. Brenske will continue to advise M1. Before joining M1 Kliniken AG, Mr. Patrick Brenske had already worked for the Haemato Group for about eight years as Head of Purchasing and Sales and led the group from a turnover in the small single-digit million range towards an annual turnover of close to 300 million euros. The attainment of the manufacturing licence in accordance with § 13 AMG (German medicines act) was one of the main drivers of HAEMATO's product business. After the acquisition of almost 50% of HAEMATO AG by M1 Kliniken AG by mid of 2020, M1 Kliniken AG follows the strategy of integrating the value chain and strengthening the product business. This offers potentials for added value - while ensuring quality. About M1 Kliniken AG M1 Kliniken AG is the leading provider of beauty medical health services in Germany. In the aesthetic and surgical field, the group offers products and services of the highest quality standards. Under the brand "M1 Med Beauty", beauty medical treatments are currently offered at more than 35 specialist centres. With six operating theatres and 35 beds, the M1 Schlossklinik für plastische und ästhetische Chirurgie in Berlin is one of the largest and most modern facilities of its kind in Europe. Since the end of 2018, M1 has been driving forward its internationalisation and is currently also active in Austria, Switzerland, the Netherlands, England and Australia. In addition, the Group markets high-quality products under the brands "M1 Select" and "M1 Aesthetics" to private customers as well as doctors, pharmacies and wholesalers. Contact us: M1 Klinken AG Grünauer Strasse 5; D-12557 Berlin T: +49 (0) 30 34 74 74 - 414 M: firstname.lastname@example.org W: www.m1-kliniken.de 30-Nov-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: M1 Kliniken AG Grünauer Straße 5 12557 Berlin Germany Phone: +49 (0)30 347 47 44 14 Fax: +49 (0)30 347 47 44 17 E-mail: email@example.com Internet: https://www.m1-kliniken.de ISIN: DE000A0STSQ8 WKN: A0STSQ Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1151538 End of Announcement DGAP News Service
Cinedigm (NASDAQ: CIDM) announced today that the Company has added over 1,000 hours of programming to its extensive library. This influx of premium content supports new internal primetime programming strategies to capture a share of the $1.2 billion projected streaming holiday ad spending this season. This move will allow Cinedigm to continue to refresh and curate high quality content across its wide range of streaming networks that reach hundreds of millions of devices.
Emles Advisors ("Emles"), an asset management firm built to solve the unique challenges of today’s markets, announces the launch of two new exchange-traded funds (ETFs) - the Emles Protective Allocation ETF (DEFN) and the Emles Luxury Goods ETF (LUXE).
Chelverton UK Dividend Trust plc (SDVP) 30-Nov-2020 / 14:29 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. CHELVERTON UK DIVIDEND TRUST PLCINTERIM DIVIDENDIn respect of the financial year ending 30 April 2021, the Company has today declared a second interim dividend in respect of the year 1 May 2020 to 30 April 2021.A second interim dividend of 2.50p (2.40p: 2019) per Ordinary share will be paid on 4 January 2021 to the holders of Ordinary shares on the register at 11 December 2020, with an ex-dividend date of 10 December 2020.Maitland Administration Services Limited - Corporate Secretary30 November 2020 * * * ISIN: GB0006615826, GB00BZ7MQD81 Category Code: DIV TIDM: SDVP LEI Code: 213800DAF47EJ2HT4P78 OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State Sequence No.: 88778 EQS News ID: 1151596 End of Announcement EQS News Service
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.KEY INFORMATION (a)Full name of discloser:Invesco Ltd. (b)Owner or controller of interests and short positions disclosed, if different from 1(a):The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c)Name of offeror/offeree in relation to whose relevant securities this form relates:Use a separate form for each offeror/offereeFuture PLC (d)If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e)Date position held/dealing undertaken:For an opening position disclosure, state the latest practicable date prior to the disclosure27 November 2020 (f)In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?If it is a cash offer or possible cash offer, state “N/A”No 2.POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security. (a)Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security:15p Ordinary GB00BYZN9041 InterestsShort Positions Number%Number% (1)Relevant securities owned and/or controlled:4,561,5264.65% (2)Cash-settled derivatives: (3)Stock-settled derivatives (including options) and agreements to purchase/sell: Total4,561,5264.65% All interests and all short positions should be disclosed. Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions). (b)Rights to subscribe for new securities (including directors’ and other employee options) Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in. The currency of all prices and other monetary amounts should be stated. (a)Purchases and sales Class of relevant securityPurchase/saleNumber of securitiesPrice per unit 15p OrdinaryPurchase14,30916.76 GBP (b)Cash-settled derivative transactions Class of relevant securityProduct description e.g. CFDNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit (c)Stock-settled derivative transactions (including options) (i)Writing, selling, purchasing or varying Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitType e.g. American, European etc.Expiry dateOption money paid/ received per unit (ii)Exercise Class of relevant securityProduct description e.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit (d)Other dealings (including subscribing for new securities) Class of relevant securityNature of dealing e.g. subscription, conversionDetailsPrice per unit (if applicable) 4.OTHER INFORMATION (a)Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none” None (b)Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:(i) the voting rights of any relevant securities under any option; or(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:If there are no such agreements, arrangements or understandings, state “none” None (c)Attachments Is a Supplemental Form 8 (Open Positions) attached?NO Date of disclosure30 November 2020 Contact nameSam Edwards Telephone number+44 1491 416381 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.
German annual consumer prices fell further in November, pushed down by a VAT cut introduced as part of the government's stimulus push to help Europe's largest economy recover from the coronavirus shock, data showed on Monday. Consumer prices, harmonised to make them comparable with inflation data from other European Union countries, fell 0.7% year-on-year after shrinking by 0.5% in the previous month, the Federal Statistics Office said. "The inflation rate is influenced, among other things, by the reduction in value-added tax that came into force on July 1, 2020," the office said in a statement.
Pop singer was criticised after pictures emerged showing her guests arriving for a private party in London
WASHINGTON (AP) — “America the Beautiful” is this year's Christmas theme at the White House. Melania Trump says it pays tribute to and showcases the “majesty" of the United States. Ornaments on the official Christmas tree in the Blue Room — a towering Fraser fir from Shepherdstown, West Virginia — were designed by students from across the country who were asked by the National Park Service to highlight the people, places and things that make their states beautiful.
General Motors will not take an initial stake in the electric vehicle company Nikola, which announced Monday that it would scuttle on of its marquee vehicles, an electric and hydrogen-powered pickup that was to be called the Badger. Shares of Nikola plunged 21% before the opening bell. Nikola on Monday released updated terms between the companies for a supply agreement related to GM's fuel-cell system , replacing an agreement signed in September.
The final day is here, and it’s the perfect time to save money on sofas, beds, coffee tables and more
Automotive IoT Market Research Report by Component (Hardware, Services, and Software), by Connectivity (Embedded, Integrated, and Tethered), by Communication, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19New York, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Automotive IoT Market Research Report by Component, by Connectivity, by Communication, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05913428/?utm_source=GNW The Global Automotive IoT Market is expected to grow from USD 26,460.71 Million in 2019 to USD 80,051.88 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 20.26%.Market Segmentation & Coverage:This research report categorizes the Automotive IoT to forecast the revenues and analyze the trends in each of the following sub-markets:Based on Component, the Automotive IoT Market studied across Hardware, Services, and Software. The Hardware further studied across Connectivity Technology ICs and Semiconductor Component. The Services further studied across Deployment & Integration Services and Support & Maintenance Services. The Software further studied across Platform and Solution. Based on Connectivity, the Automotive IoT Market studied across Embedded, Integrated, and Tethered. Based on Communication, the Automotive IoT Market studied across In-Vehicle Communication, Vehicle-To-Infrastructure Communication, and Vehicle-To-Vehicle Communication. Based on Application, the Automotive IoT Market studied across Infotainment, Navigation, and Telematics. The Infotainment further studied across Communication and Entertainment. The Navigation further studied across Real-Time Data Capture and Road & Vehicle Monitoring. The Telematics further studied across Collission Avoidance, Emergency Vehicle Notification, Fleet & Asset Management, Intelligent Traffic System, Parking Management System, Passenger Information System, Predictive Maintainance, and Remote Monitoring & Diagnostics. Based on Geography, the Automotive IoT Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Automotive IoT Market including Apple, Inc., AT&T Inc., Audi AG, Cisco Systems, Inc., Ford Motor Company, General Motors, Google Inc., IBM Corporation, Intel Corporation., Microsoft Corporation, NXP Semiconductors N.V., Texas Instruments Inc., Thales Sa, and Tomtom N.V.. FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Automotive IoT Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developmentsThe report answers questions such as:1. What is the market size and forecast of the Global Automotive IoT Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Automotive IoT Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Automotive IoT Market?4. What is the competitive strategic window for opportunities in the Global Automotive IoT Market?5. What are the technology trends and regulatory frameworks in the Global Automotive IoT Market?6. What are the modes and strategic moves considered suitable for entering the Global Automotive IoT Market?Read the full report: https://www.reportlinker.com/p05913428/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
Actor and talk show host said that bullies don’t like confident people
British singer Rita Ora apologized Monday for breaking lockdown rules by holding a birthday party, saying it was “a serious and inexcusable error of judgment.” The Sun newspaper ran photos of Ora and others, including models Cara and Poppy Delevingne, arriving at the Casa Cruz restaurant in London’s Notting Hill area on Saturday. Under lockdown rules that end Wednesday, all pubs and restaurants in England must close except for takeout and delivery, and people are barred from meeting indoors with members of other households.
David Keys explains how the world’s best-known medieval outlaw and another outlaw, Robert of Wetherby, may actually have been the same person
Moderna Inc. said it would ask U.S. and European regulators Monday to allow emergency use of its COVID-19 vaccine as new study results confirm the shots offer strong protection — ramping up the race to begin limited vaccinations as the coronavirus rampage worsens. Multiple vaccine candidates must succeed for the world to stamp out the pandemic, which has been on the upswing in the U.S. and Europe. U.S. hospitals have been stretched to the limit as the nation has seen more than 160,000 new cases per day and more than 1,400 daily deaths. Since first emerging nearly a year ago in China, the virus has killed more than 1.4 million people worldwide.Moderna is just behind Pfizer and its German partner BioNTech in seeking to begin vaccinations in the U.S. in December. British regulators also are assessing the Pfizer shot and another from AstraZeneca.Moderna created its shots with the U.S. National Institutes of Health and already had a hint they were working, but said it got the final needed results over the weekend that suggest the vaccine is more than 94% effective.Of 196 COVID-19 cases so far in its huge U.S. study, 185 were trial participants who received the placebo and 11 who got the real vaccine. The only people who got severely ill — 30 participants, including one who died — had received dummy shots, said Dr. Tal Zaks, the Cambridge, Massachusetts, company's chief medical officer.When he learned the results, “I allowed myself to cry for the first time,” Zaks told The Associated Press. “We have already, just in the trial, have already saved lives. Just imagine the impact then multiplied to the people who can get this vaccine.”Moderna said the shots’ effectiveness and a good safety record so far — with only temporary, flu-like side effects — mean they meet requirements set by the U.S. Food and Drug Administration for emergency use before the final-stage testing is complete. The European Medicines Agency, Europe’s version of FDA, has signaled it also is open to faster “conditional" clearance.What comes nextThe FDA has pledged that before it decides to roll out any COVID-19 vaccines, its scientific advisers will publicly debate whether there’s enough evidence behind each candidate.First up on Dec. 10, Pfizer and BioNTech will present data suggesting their vaccine candidate is 95% effective. Moderna said its turn at this “science court” is expected exactly a week later, on Dec. 17.If the FDA allows emergency use, Moderna expects to have 20 million doses ready for the U.S. by year’s end. Recipients will need two doses, so that’s enough for 10 million people.Pfizer expects to have 50 million doses globally in December. Half of them — or enough for 12.5 million people — are earmarked for the U.S.Shipments are set to begin to states within 24 hours of FDA clearance. And this week, a different panel of U.S. experts, established by the Centers for Disease Control and Prevention, will meet to decide how those initial supplies will be given out. They're expected to reserve scarce first doses for health care workers and, if the shots work well enough in the frail elderly, for residents of long-term care facilities.As more vaccine gradually becomes available in coming months, other essential workers and people at highest risk from the coronavirus would get in line. But enough for the general U.S. population isn't expected until at least spring.Outside the U.S., Zaks said significant supplies from Moderna would be available later, “in the first quarter” of next year.“Obviously we are doing everything in our power to increase the capacity and accelerate the timelines,” he said.Britain's government said Sunday it has ordered 7 million doses from Moderna.The U.K. also has ordered 40 million doses of the Pfizer-BioNTech vaccine, although it's not clear how much of the companies' limited December supply could go toward that order — if British health authorities clear the shots. Still, British hospitals are gearing up to receive some doses as early as next week.Both Moderna's and Pfizer's vaccines are made with the same technology, using a piece of genetic code for the “spike” protein that studs the virus. That messenger RNA, or mRNA, instructs the body to make some harmless spike protein, training immune cells to recognize it if the real virus eventually comes along.AstraZeneca confusionAstraZeneca and Oxford University last week announced confusing early results of their vaccine candidate from research in Britain and Brazil.That vaccine appears 62% effective when tested as originally intended, with recipients given two full doses. But because of a manufacturing error, a small number of volunteers got a lower first dose — and AstraZeneca said in that group, the vaccine appeared to be 90% effective.Experts say it’s unclear why the lower-dose approach would work better and that it may just be a statistical quirk.A larger U.S. study of the AstraZeneca candidate still is underway that should eventually give the FDA a better picture of how well it works. The FDA has said any COVID-19 vaccine would have to be at least 50% effective.Meanwhile Britain’s government will have to decide whether its U.K. data is sufficient for an early rollout there.Still in the pipelineJohnson & Johnson also is in final-stage testing in the U.S. and several other countries to see if its vaccine candidate could work with just one dose.Both the J&J and AstraZeneca vaccines work by using harmless cold viruses to carry the spike protein gene into the body and prime the immune system.The different technologies have ramifications for how easily different vaccines could be distributed globally. The AstraZeneca shots won't require freezer storage like the Pfizer and Moderna vaccines.Candidates made with still other technologies are in late-stage testing, too. Another U.S. company, Novavax Inc., announced Monday that it has finished enrolling 15,000 people in a late-stage study in Britain and plans to begin recruiting even more volunteers for final testing in the U.S. and Mexico “in the coming weeks.”Vaccines made by three Chinese companies and a Russian candidate also are being tested in thousands of people in countries around the world.(AP)
Spain appeals for Covid 'common sense' after weekend crowd scenesMinister urges people across country to behave responsibly amid second coronavirus wave * Coronavirus – latest updates * See all our coronavirus coverage
She told fellow panellists that the pandemic made her question what she wanted from life.
Reports have suggested Boris Johnson’s dog, Dilyn, was unwell when the PM had coronavirus in April
Pope Francis has cancelled a ceremony that traditionally begins Rome's Christmas season on Dec. 8 at the Spanish Steps because of coronavirus restrictions, the Vatican said on Monday. The pope customarily places a wreath of flowers at the base of a 12-metre column bearing a statue of the Madonna and blesses from a distance another wreath already placed around the statue's arm by firefighters using a ladder. The Vatican said Francis would skip the ceremony, which popes have been carrying out on the feast of the Immaculate Conception since 1953, "in order to avoid any risk of contagion caused by gatherings of people".